Alkermes Brushes Off IP Pressures To Look to Potential Blockbuster Vivitrol
Recent intellectual property rulings have potentially been both positive and negative for specialty company Alkermes, which is still forecasting growing revenues driven by its marketed opioid addiction therapy and progress with its Phase III CNS products pipeline.
You may also be interested in...
First quarter VC investments in biopharma set high expectations for the second quarter; Acorda cuts jobs after patent litigation defeat, plus other strategic realignments; no new US IPOs, but Europe has three; and notable follow-on offerings.
In an unusual twist, district court ruled Acorda patents invalid after company defeated Kyle Bass' inter partes review challenge; Bass has won 10 IPR decisions, lost 9 and has one pending.
Boehringer Ingelheim’s sales were driven by Jardiance and Ofev in the first half of 2020, with contract manufacturing contributing with a 16% increase in sales; more details from the EMPEROR-Reduced Phase III study in heart failure are expected at this month’s European College of Cardiology meeting.